Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
Unlock the market timeline & signal feed
New Product & Tech activity — 3 fresh signals just appeared.
The order this company entered each market — oldest to newest
Maximize as afirmações de mobilidade com o colágeno UC-II®
Sign up to see the full signal feed
How Lonza's international expansion compares to its competitors
LonzaYouBars show relative size across the companies compared.
5 metrics| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 LonzaYou | 25 | 0 | -18% | 987 | 33 |
Scaling fast — 910 roles opened in the last 90 days, up 326% vs the prior period. Engineering-led and concentrated in Switzerland.
Slough, England, United Kingdom · 2d ago
Associate Principal QA Specialist
Gurugram, Haryana, India · yesterday
IT Commercial Head
Visp, Valais, Switzerland · 2d ago
Internship within HR Operations Switzerland Team
36 technologies detected across the stack.
14 active campaigns across 188 markets.
Ended18 mentions in the last 90 days.
Harbour BioMed reported H1 2026 revenue of RMB 834M (up 20.9% YoY), net profit of RMB 442M, marking seventh consecutive half-year profit, with multiple clinical milestones and strategic partnerships.
AI-based antibody drug development platform Mirabo Biotechnology raised 4 billion KRW ($3M) in Pre-Series A funding led by Stonebridge Ventures with FuturePlay participation, using its MiRAiQ AI engine.
Artisan Partners initiated positions in GE Aerospace, Corning, STMicroelectronics, and Robinhood during Q4, while adding to DoorDash and Keyence. The firm exited Cencora, Lonza Group, and Medline, and trimmed holdings in AMD, Lam, Amer Sports, and Tencent.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Lonza's business, markets, and growth signals.
“We reach accounts the week they land in-market — not the quarter after.”
Book a walkthrough of the movement map with our team.
Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.
© 2026 Pubrio. All rights reserved.
